Physiomics PLC - Oncology consultancy based in Oxford, England - Says it has been awarded a further contract by existing client Ankyra Therapeutics. The contract builds on work announced in March, and is expected to complete in the first quarter of 2023.
Ankyra is a Boston-based biotech company focused on improving both the safety and efficacy of cancer treatment through its proprietary anchored immunotherapy platform. Physiomics is supporting Ankyra with the modelling and simulation of ANK-101, its lead molecule, in immune-oncology settings.
Chief Executive Officer Jim Millen says: ‘We are delighted to continue supporting Ankyra Therapeutics for the development of this exciting new molecule ANK-101 through the use of modelling and simulation.’
Current stock price: 2.48 pence, up 13% on Thursday afternoon in London
12-month change: down 63%
Copyright 2022 Alliance News Limited. All Rights Reserved.
